United Therapeutics
UTHR
885 hedge funds and large institutions have $22.6B invested in United Therapeutics in 2026 Q2 according to their latest regulatory filings, with 107 funds opening new positions, 319 increasing their positions, 333 reducing their positions, and 70 closing their positions.
53% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 70
27% more capital inflows, than outflows
Capital inflows: $2.92B | Capital outflows: $2.3B
3.6% more ownership
Funds ownership: 94.72% → 98.32% (+3.6%)
4% more funds holding
Funds holding: 855 → 885 (+30)
4% less call options, than puts
Call options by funds: $609M | Put options by funds: $633M
4% less repeat investments, than reductions
Existing positions increased: 319 | Existing positions reduced: 333
31% less funds holding in top 10
Funds holding in top 10: 26 → 18 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vestal Point Capital
New York
|
+$203M |
| 2 |
Jane Street
New York
|
+$159M |
| 3 |
Millennium Management
New York
|
+$144M |
| 4 |
Bellevue Group
Kuesnacht,
Switzerland
|
+$105M |
| 5 |
Avoro Capital Advisors
New York
|
+$83.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$499M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$158M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$133M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$91.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$76.2M |
UTHR Hedge Fund Activity: Q2 2026 in Review
885 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2026, worth a combined $22.6B — down 7.9% from $24.6B a quarter earlier.
Buyers outnumbered sellers: 107 funds opened new UTHR positions and 70 closed out — a net gain of 37 holders — while 319 added to existing stakes and 333 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $203M. The largest seller was Wellington Management Group, cutting an estimated $499M.
- 885 institutional investors held United Therapeutics (UTHR) as of Q2 2026, up from 855 in Q1 2026.
- Funds reported $22.6B of United Therapeutics stock for Q2 2026, down 7.9% quarter-over-quarter.
- 107 funds opened new United Therapeutics positions in Q2 2026 and 70 closed out, a net change of +37 holders.
- The largest United Therapeutics buyer in Q2 2026 was Vestal Point Capital, an estimated $203M added.
- The largest United Therapeutics seller in Q2 2026 was Wellington Management Group, an estimated $499M sold.
Based on aggregated 13F filings for Q2 2026.